TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI's AVC Solution

What happened

Nanox said updated clinical data on its HealthAVC software was presented at the October 31–November 3, 2026, TCT conference in San Diego. The software analyzes routine chest CT images to measure aortic valve calcium, but remains under development and is not cleared for clinical use or commercially available.

Confirmed

Global impact / market context

If cleared and adopted, HealthAVC could help clinicians identify calcium findings on scans taken for other reasons, potentially prompting further heart evaluation and monitoring. For Nanox, that could create a future software revenue opportunity, but the article gives no clearance, sales, or adoption evidence.

Analyst inference

The headline describes an 84% reporting gap, but the supplied article text does not provide the study details behind that figure. The disclosed product is still developmental, so any commercial opportunity depends on clinical evidence, regulatory clearance, and eventual use in routine imaging workflows.

Analyst inference

What to watch

1. Whether Nanox publishes full clinical-study details, including how the 84% reporting gap was measured and which patient scans were included, would clarify the evidence. Analyst inference
2. Whether HealthAVC receives regulatory clearance matters because the article says it is not yet cleared for clinical use or commercially available. Confirmed
3. Any evidence of hospital adoption or payment arrangements could show whether the software can generate revenue and fit into routine CT workflows after clearance. Analyst inference

Evidence

• globenewswire.com